Literature DB >> 12969958

FOP-FGFR1 tyrosine kinase, the product of a t(6;8) translocation, induces a fatal myeloproliferative disease in mice.

Geraldine Guasch1, Bénédicte Delaval, Christine Arnoulet, Min-Jue Xie, Luc Xerri, Danielle Sainty, Daniel Birnbaum, Marie-Joséphe Pébusque.   

Abstract

Constitutive activation of aberrant fibroblast growth factor receptor 1 (FGFR1) kinase as a consequence of gene fusion such as FOP-FGFR1 associated with t(6; 8)(q27;p11-12) translocation, is the hallmark of an atypical aggressive stem cell myeloproliferative disorder (MPD) in humans. In this study, we show that expression of FOP-FGFR1 in primary bone marrow cells induced by retroviral transduction generates a MPD in mice. Constitutive FOP-FGFR1 kinase activity was both essential and sufficient to cause a chronic myeloproliferative syndrome in the murine bone marrow transplantation model. In contrast to the human disorder, lymphoproliferation and progression to acute phase were not observed. Lymphoid symptoms, however, appeared when onset of the disease was delayed as the result of mutation of FOP-FGFR1 at tyrosine 511, the phospholipase C gamma (PLCgamma) binding site.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12969958     DOI: 10.1182/blood-2003-05-1690

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  13 in total

1.  Growth factor receptors as regulators of hematopoiesis.

Authors:  Michael A Weinreich; Ingrid Lintmaer; Linlin Wang; H Denny Liggitt; Michael A Harkey; C Anthony Blau
Journal:  Blood       Date:  2006-08-10       Impact factor: 22.113

Review 2.  Roles of FGFR in oral carcinogenesis.

Authors:  Xiaoyan Xie; Zhiyong Wang; Fangman Chen; Yao Yuan; Jiayi Wang; Rui Liu; Qianming Chen
Journal:  Cell Prolif       Date:  2016-06       Impact factor: 6.831

3.  14-3-3 Integrates prosurvival signals mediated by the AKT and MAPK pathways in ZNF198-FGFR1-transformed hematopoietic cells.

Authors:  Shaozhong Dong; Sumin Kang; Ting-Lei Gu; Sean Kardar; Haian Fu; Sagar Lonial; Hanna Jean Khoury; Fadlo Khuri; Jing Chen
Journal:  Blood       Date:  2007-03-27       Impact factor: 22.113

4.  A novel chromosomal abnormality, t(6;10)(q27;q22), found in a polycythemic potential donor for allogeneic hematopoietic stem cell transplantation.

Authors:  Hideki Mitsui; Norimitsu Saito; Atsushi Satake; Tsuyoshi Nakazawa; Takahiro Karasuno; Akira Hiraoka
Journal:  Int J Hematol       Date:  2005-07       Impact factor: 2.490

5.  PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder.

Authors:  Jing Chen; Daniel J Deangelo; Jeffery L Kutok; Ifor R Williams; Benjamin H Lee; Martha Wadleigh; Nicole Duclos; Sarah Cohen; Jennifer Adelsperger; Rachel Okabe; Allison Coburn; Ilene Galinsky; Brian Huntly; Pamela S Cohen; Thomas Meyer; Doriano Fabbro; Johannes Roesel; Lolita Banerji; James D Griffin; Sheng Xiao; Jonathan A Fletcher; Richard M Stone; D Gary Gilliland
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-24       Impact factor: 11.205

6.  A PP2A phosphatase high density interaction network identifies a novel striatin-interacting phosphatase and kinase complex linked to the cerebral cavernous malformation 3 (CCM3) protein.

Authors:  Marilyn Goudreault; Lisa M D'Ambrosio; Michelle J Kean; Michael J Mullin; Brett G Larsen; Amy Sanchez; Sidharth Chaudhry; Ginny I Chen; Frank Sicheri; Alexey I Nesvizhskii; Ruedi Aebersold; Brian Raught; Anne-Claude Gingras
Journal:  Mol Cell Proteomics       Date:  2008-09-08       Impact factor: 5.911

7.  The 8p11 myeloproliferative syndrome: review of literature and an illustrative case report.

Authors:  Ami Goradia; Michael Bayerl; Dennis Cornfield
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

8.  Identification of a minimal region of loss on chromosome 6q27 associated with poor survival of high-risk neuroblastoma patients.

Authors:  Marzia Ognibene; Martina Morini; Alberto Garaventa; Marina Podestà; Annalisa Pezzolo
Journal:  Cancer Biol Ther       Date:  2020-01-20       Impact factor: 4.742

9.  Centrosome-kinase fusions promote oncogenic signaling and disrupt centrosome function in myeloproliferative neoplasms.

Authors:  Joanna Y Lee; Wan-Jen Hong; Ravindra Majeti; Tim Stearns
Journal:  PLoS One       Date:  2014-03-21       Impact factor: 3.240

Review 10.  Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1.

Authors:  Ayalew Tefferi
Journal:  J Cell Mol Med       Date:  2008-10-23       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.